金龙胶囊联合肝动脉化疗栓塞治疗原发性肝癌疗效观察

Clinical Studies on the Combination Therapy with Jinlong Capsule and Chemotherapy plus Embolization by Hepatic Artery Catheterization on Primary Hepatic Carcinoma

目的:探讨金龙胶囊对原发性肝癌的治疗作用。方法:224例不能手术的原发性肝癌患者随机分为金龙胶囊联合肝动脉化疗栓塞组(治疗组116例)及单纯肝动脉化疗栓塞组(对照组108例),观察治疗后6个月、1、2、3年疗效、生存率和生活质量。结果:治疗组治疗后1、2、3年生存率为77.6%、47.4%、19.8%,对照组为64.8%、34.3%、10.2%,治疗组明显优于对照组(P<0.05);治疗组各项生活质量评分明显优于对照组(P<0.05);两组治疗后有效率比较无显著性差异(P>0.05)。结论:金龙胶囊可显著提高原发性肝癌患者的生存时间和生活质量,是治疗原发性肝癌的有效药物。

Objective: To study the clinical effect of Jinlong capsule on primary hepatic carcinoma (PHC). Method: A total of 224 cases with PHC, who failed to be treated by operation, were classified randomly into two groups: combination therapy group (treat group, 116 cases) and chemotherapy and embolization group (control group, 108 cases). The effect, survival rate and life quality was respectively evaluated at 6 months, 1, 2 and 3 years after treatment. Results: The survival rate and life quality of treatment group were better than control group significantly (P<0.05) at 1, 2 and 3 years after treatment. Conclusions: Jinlong capsule can significantly improve the survival time and life quality of patients with PHC. It is an effective drug for the treatment of PHC.